Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Get match with Excessive Health and assist help the Ronald McDonald Home
You can support the Ronald McDonald House Charities of the Central Valley this weekend and train with high fitness.
High Fitness is holding a...